Sensors glean information from radiofrequency ID chips embedded in labels of contrast bottles
VistaTrak looks like a basic cabinet designed to hold bottles of contrast media. Wall-hung and compact, it seems a practical way to keep these bottles handy for use. But mounted to the side of this cabinet is a touchscreen that hints that VistaTrak may be more than it appears.
Lying in wait beneath its simple exterior are sensors that pick up signals from radiofrequency identification (RFID) chips attached to bottles of contrast. These signals indicate the lot number, expiration date, and other information when each bottle is removed from the cabinet. VistaTrak transmits these data to an inventory management system so managers can track the use of contrast and determine when stocks need to be replenished. It even checks automatically for compliance with dosing protocols.
“VistaTrak allows hospitals to not only track their inventory of contrast agents but to watch for patient safety issues, which are becoming critically important when contrast agents are used in an MR or CT suite,” said Douglas Stefanelli, vice president and general manager of diagnostic imaging for Bayer HealthCare Pharmaceuticals. “It also helps compliance with Joint Commission on Accreditation of Healthcare Organizations standards.”
When linked to an electronic medical record or radiology information system, the high-tech cabinet can flag information that may affect the use of contrast material, such as a patient’s glomerular filtration rate (an indicator of kidney disease) or potential allergic reactions, a cochlear implant, or a pacemaker. The password-protected cabinet further safeguards patients by restricting access to staff who are provided specially designed badges or PIN codes.
Previewed by Bayer at RSNA 2007, VistaTrak is scheduled to begin shipping in mid-2008. Bayer’s MR contrast agent Magnevist will be the first to carry a VistaTrak RFID tag.
The cabinet answers some of the challenges facing providers who are being tasked by federal and state regulators, as well as JCAHO, to reduce medication errors. It addresses them in an automated and cost-effective way, according to Scott Bertetti, Bayer’s associate director of business development for diagnostic imaging, using technnology developed by Mobile Aspects and customized by Bayer and Mobile Aspects specifically for the radiology department.
“We created a small cabinet, because real estate is at a premium in the radiology area,” Bertetti said. “We also changed the interface to fit workflow in the radiology department and to address Joint Commission concerns about the use of contrast.”
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.